[1] |
Cheng YY, Jin H, Liu X, et al. Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. Br J Cancer, 2008, 99(12):2083-2087.
|
[2] |
Pupa SM, Argraves WS, Forti S, et al. Immunological and pathobiological roles of fibulin-1 in breast cancer. Oncogene,2004, 23(12):2153-2160.
|
[3] |
Bardin A, Moll F, Margueron R, et al. Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology,2005, 146(2):760-768.
|
[4] |
Wlazlinski A, Engers R, Hoffmann MJ, et al. Downregulation of several fibulin genes in prostate cancer. Prostate,2007, 67(16):1770-1780.
|
[5] |
Timpl R, Sasaki T, Kostka G, et al. Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol,2003, 4(6):479-489.
|
[6] |
Weigell-Weber M, Sarra GM, Kotzot D, et al. Genomewide homozygosity mapping and molecular analysis of a candidate gene located on 22q13 (fibulin-1) in a previously undescribed vitreoretinal dystrophy. Arch Ophthalmol, 2003, 121(8):1184-1188.
|
[7] |
Kubota Y, Kuroki R, Nishiwaki K. A fibulin-1 homolog interacts with an ADAM protease that controls cell migration in C. elegans. Curr Biol, 2004, 14(22):2011-2018.
|
[8] |
Cangemi C, Skov V, Poulsen MK, et al. Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. Clin Chem, 2011, 57(11):1556-1565.
|
[9] |
Courtney HS, Li Y, Twal WO, et al. Serum opacity factor is a streptococcal receptor for the extracellular matrix protein fibulin-1. J Biol Chem, 2009, 284(19):12966-12971.
|
[10] |
Piscaglia F, Dudás J, Knittel T, et al. Expression of ECM proteins fibulin-1 and -2 in acute and chronic liver disease and in cultured rat liver cells. Cell Tissue Res, 2009, 337(3):449-462.
|
[11] |
Clinton GM, Rougeot C, Derancourt J, et al. Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc Natl Acad Sci U S A,1996, 93(1):316-320.
|
[12] |
Qing J, Maher VM, Tran H, et al. Suppression of anchorage-independent growth and matrigel invasion and delayed tumor formation by elevated expression of fibulin-1D in human fibrosarcoma-derived cell lines. Oncogene, 1997, 15(18):2159-2168.
|
[13] |
Hayashido Y, Lucas A, Rougeot C, et al. Estradiol and fibulin-1 inhibit motility of human ovarian- and breast-cancer cells induced by fibronectin. Int J Cancer,1998, 75(4):654-658.
|
[14] |
Perbal B, Martinerie C, Sainson R, et al. The C-terminal domain of the regulatory protein NOVH is sufficient to promote interaction with fibulin 1C: a clue for a role of NOVH in cell-adhesion signaling. Proc Natl Acad Sci U S A, 1999, 96(3):869-874.
|
[15] |
Gallagher WM, Currid CA, Whelan LC. Fibulins and cancer: friend or foe? Trends Mol Med, 2005, 11(7):336-340.
|
[16] |
Kuo PL, Shen KH, Hung SH, et al. CXCL1/GROα increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-κB/HDAC1 epigenetic regulation. Carcinogenesis, 2012, 33(12):2477-2487.
|
[17] |
Kanda M, Nomoto S, Okamura Y, et al. Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog, 2011, 50(8):571-579.
|
[18] |
Argraves WS, Tanaka A, Smith EP, et al. Fibulin-1 and fibrinogen in human atherosclerotic lesions. Histochem Cell Biol, 2009, 132(5):559-565.
|